Medherant, a Coventry, UK-based biotechnology company advancing a testosterone patch for women with menopausal symptoms, raised £3M in funding.
Mercia Asset Management made the investment.
The company intends to use the funds to accelerate its growth and research efforts.
Led by CEO John Burt, Medherant is a clinical-stage company developing a testosterone replacement patch for women with menopausal symptoms, which is based on a proprietary adhesive developed by its scientists. The patch delivers the correct amount and would have to be changed twice a week. The University of Warwick spin-out aims to begin clinical trials later this year and to gain regulatory approval in the UK and internationally.
FinSMEs
04/04/2023